CervoMed raises $10.5M in private placement; shifts focus to strategic partnering for neflamapimod in DLB

CervoMed Inc.

Gross proceeds ~$10.5M from sale of 3.36M units at $3.14 each; up to $21.7M additional if warrants fully exercised.
Insiders including chair Joshua Boger, CEO John Alam trusts, and director Sylvie Grégoire purchased ~1.37M units.
Net proceeds extend cash runway into Q2 2027; funds neflamapimod R&D and general corporate purposes.
Strategic priority to find a partner for Phase 3 in dementia with Lewy bodies after FDA/EMA alignment on registration path.
Near-term milestones: nfvPPA Phase 2a clinical data Q1 2027; ALS Phase 2a trial initiation Q4 2026.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CervoMed Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $10.5 million (effective 2026-06-09).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: approximately $10.5 million
Effective: 2026-06-09

Exact text from the filing

On June 9, 2026, CervoMed Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors named therein (each, an “Investor” and collectively, the “Investors”), for the private placement (the “Private Placement”) of an aggregate of 3,360,377 units (the “Units”)

View on SEC.gov

802 material agreements filed in the last 30 days. Browse all material agreements →

CervoMed Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-020080

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.